Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2024. A summary of the consolidated financial statements is included below.
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
Seeking Alpha / 57 minutes from now 1 Views
Comments